Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported encouraging interim results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) in first-line Large B-cell Lymphoma (LBCL). The analysis showed significantly higher minimal residual disease (MRD) clearance in the cema-cel arm versus observation (58.3% vs 16.7%) with no treatment-related ser…